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Objectives: The TBX5 gene, a member of the T-box family, is associated with congenital heart disease,
electrocardiographic parameters, and development of atrial ﬁbrillation in the general population. This
study aimed to elucidate the role of TBX5 gene polymorphisms in metabolic and inﬂammatory proﬁles
possibly linked to TBX5-related pathologies.
Materials and Methods: A sample population of 597 individuals having routine health examinations was
enrolled. Five tagging TBX5 single nucleotide polymorphisms (SNPs) were analyzed using polymerase
chain reaction and restriction enzyme digestion or TaqMan SNP genotyping assays. Associations between
genotypes/haplotypes and matrix metalloproteinase 9 (MMP9) levels were investigated using general-
ized linear model analysis. Interactions between each genotype/haplotype, MMP9 level, and obesity
status were tested using two-way analysis of variance with Golden Helix SVS Win32 7.3.1 software.
Results: After adjusting for clinical covariates, TBX5 genotypes were found to be associated with MMP9
levels (p ¼ 0.002 and p ¼ 0.001 for rs4113925 and rs3825214, respectively) in a dominant inheritance
model. Haplotype analysis using three tag SNPs (rs11067101, rs1247973, and rs3825214) revealed a
signiﬁcant association between TBX5 haplotype GCG and MMP9 levels (uncorrected p ¼ 0.0093 and the
corrected false discovery rate p ¼ 0.0435). Multivariate analysis identiﬁed that SNP rs3825214, in
addition to the MMP9 and E-selectin genotypes, was independently associated with MMP9 levels
(p < 0.001). Using a dominant inheritance model, subgroup and interaction analysis showed associations
between the rs4113925, rs3825214, and MMP9 levels only in nonobese individuals (p ¼ 1.04  104 and
p ¼ 7.11  105, respectively; interaction p ¼ 0.009 and 0.018, respectively). Subgroup analysis showed a
borderline signiﬁcant association between haplotype GCG and MMP9 levels (uncorrected p ¼ 0.020 and
corrected false discovery rate p ¼ 0.073), but with no evidence of interaction.
Conclusion: TBX5 genotypes/haplotypes are independently associated with MMP9 in Taiwanese in-
dividuals and occur predominantly in nonobese people. These associations may broaden our under-
standing of the mechanism underlying T-box family gene activity and related cardiovascular pathologies.
Copyright © 2015, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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T-box genes encode a family of transcriptional regulators that
bind via a highly evolutionary conserved DNA-binding domain, the
T-box, to cognate DNA elements (T-box-binding elements) inby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Clinical and biochemical characteristics of the study participants stratiﬁed by
gender.
Total Men Women p
No. 597 314 283
Age (y) 45.5 ± 10.1 44.6 ± 10.1 46.5 ± 9.9 0.018
Body mass index
(kg/m2)
24.3 ± 3.5 25.0 ± 3.2 23.6 ± 3.7 <0.001
Current
smoker (%)
19.4 33.4 3.9 <0.001
CRP (mg/L) 1.6 ± 6.1 1.9 ± 7.9 1.4 ± 3.1 0.065
Fibrinogen
(mmol/L)
264.0 ± 69.6 261.8 ± 71.5 266.4 ± 67.5 0.414
SELE (mg/L) 53.5 ± 26.6 60.7 ± 28.4 45.5 ± 21.9 <0.001
SELP (ng/mL) 140.3 ± 116.9 155.4 ± 131.6 123.6 ± 95.7 <0.001
SAA (mmol/L) 6.2 ± 15.6 7.2 ± 19.8 5.1 ± 9.0 0.240
sICAM1 (mg/L) 241.8 ± 112.3 245.5 ± 111.9 237.5 ± 112.8 0.435
sVCAM1 (mg/L) 491.5 ± 132.4 495.8 ± 149.9 486.8 ± 109.9 0.504
MMP1 (pg/mL) 459.4 ± 1136.2 338.3 ± 549.8 593.3 ± 1534.7 0.747
MMP2 (ng/mL) 126.8 ± 41.0 123.7 ± 41.6 130.2 ± 40.0 0.016
MMP9 (ng/mL) 144.0 ± 112.45 155.8 ± 116.3 130.8 ± 106.7 <0.001
sTNFRII (pg/mL) 3269.3 ± 948.3 3338.9 ± 996.8 3192.2 ± 887.0 0.061
Continuous variables are presented as mean ± standard deviation. SAA, CRP,
sICAM1, sVCAM1, SELE, SELP, MMP1, and MMP9 values were transformed loga-
rithmically before statistical testing tomeet the assumption of normal distributions;
however, untransformed data are shown.
CRP¼ C-reactive protein; MMP ¼ matrix metalloproteinase; SAA ¼ serum amyloid
A; SD ¼ standard deviation; SELE ¼ soluble E-selectin; SELP ¼ soluble P-selectin;
sICAM1¼ soluble intercellular adhesive molecule 1; sVCAM1¼ soluble vascular cell
adhesive molecule 1; sTNFRII ¼ soluble tumor necrosis factor receptor II.
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riety of developmental contexts [1e3]. To date, more than 20
different mammalian T-box genes have been identiﬁed, many of
which have orthologs in various multicellular organisms.
The T-box genes exhibit diverse patterns of spatial and temporal
expression in embryonic development. Developmental functions of
the T-box genes range from the speciﬁcation of the primary germ
layers by genes to later roles in limb development [4e6] and also
include speciﬁcation of cell identity during organogenesis in cardiac
development [7e9]. The biologically important roles of several
members of this gene family were further emphasized by clinical
studies demonstrating that mutations in T-box genes are associated
withnumerousdisease states inhumansandby theobservation that
T-box genes are ampliﬁed in a subset of cancers [10,11].
TBX5, a member of the T-box family, is critical for forelimb
development and cardiogenesis [1,2,12]. TBX5 independently pro-
motes cardiac chamber formation in vertebrates [13]. Song et al [14]
and Qian et al [15] also showed that four transcription factors, GATA
binding protein 4 (GATA4), heart- and neural crest derivative-
expressed protein 2, myocyte-speciﬁc enhancer factor 2C, and
TBX5, are capable of reprogramming adult mouse ﬁbroblasts into
functional cardiac-like myocytes in vitro and in vivo, and that
expression of these factors in noncardiomyocytes enhances the
function of injured hearts following myocardial infarction. Hap-
loinsufﬁciency of TBX5 causes HolteOram syndrome, an autosomal
dominant disorder characterized by upper limb malformations and
cardiac septation defects. TBX5 gene mutations have also been asso-
ciated with atrial septal defect, ventricular septal defect, and atrio-
ventricular (AV) block [10,16]. TBX5 gene polymorphisms have been
associated with genetic determinants of the PR interval, QRS dura-
tion, and development of atrial ﬁbrillation in the general population
[17,18]. Kimetal [19]alsoobserved thatgeneticpolymorphisms in the
TBX5geneareassociatedwith the riskofmetabolic syndrome.Herein,
TBX5 genotypes/haplotypes were analyzed in 597 Taiwanese in-
dividuals to further elucidate the role of the TBX5 gene in metabolic
and inﬂammatory proﬁles associatedwith TBX5-related pathologies.
2. Materials and Methods
2.1. Study population
After written informed consent was obtained, the study par-
ticipants, who had no known history of major systemic or cardio-
vascular diseases, were recruited during routine health
examinations. Exclusion criteria included cancer, current renal or
liver disease, and a history of myocardial infarction, stroke, or
transient ischemic attacks. In addition, patients taking diabetes
mellitus and/or lipid-lowering drugs during the period of blood
sample collection were excluded from the analysis because previ-
ous reports revealed that these agents affect inﬂammation marker
expression or concentrations [20e22]. A total of 597 study partic-
ipants [314 men with a mean age (± standard deviation) of
44.6 ± 10.1 years and 283 women with a mean age of 46.55 ± 9.9
years] were enrolled in the study. The clinical and biometric fea-
tures of the study group are summarized in Table 1. Obesity was
deﬁned as a body mass index of 25 kg/m2 or above, according to
Asian criteria [23]. Current smokers were deﬁned as individuals
who smoked cigarettes regularly at the time of survey. The Ethics
Committee of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical
Foundation, New Taipei City, Taiwan, approved the investigation.
2.2. Laboratory examination
Prior to starting the study, all participants underwent an initial
screening assessment that includedmedical history, vital signs, andmeasurement of lipid variables and novel risk factors. A total of
15 mL of venous blood was collected in the morning after an
overnight (8e12-hour) fast. Venous blood samples were collected
from an antecubital vein with a 21-gauge needle. Serum, EDTA,
sodium ﬂuoride, and sodium citrate plasma samples were obtained
by centrifugation at 3000g for 15 minutes at 4C. Immediately after
centrifugation, serum/plasma samples were frozen and stored
at 80C prior to analysis. All measurements were performed in a
central laboratory.
2.3. Assays
Most markers, including serum C-reactive protein, serum amy-
loid A, soluble intercellular adhesive molecule 1, soluble vascular
cell adhesive molecule 1, soluble E-selectin (SELE), matrix metal-
loproteinase (MMP) 2, andMMP9weremeasured using a sandwich
enzyme-linked immunosorbent assay (ELISA) developed in house.
All in-house kits showed good correlation when compared with
commercially available ELISA kits [24e26]. Circulating plasma
MMP1, soluble P-selectin, and soluble tumor necrosis factor re-
ceptor II were measured using commercially available ELISA kits
from R&D (Minneapolis, MN, USA).
2.4. Genomic DNA extraction and genotyping
Genomic DNA was extracted as previously reported [27,28].
From the published sequence of the TBX5 gene, oligonucleotide
primers were generated to amplify fragments of genomic DNA
containing genetic polymorphisms reported on the National Center
for Biotechnology Information single nucleotide polymorphism
(SNP) database (http://www.ncbi.nlm.nih.gov/SNP). Based on the
HapMap database, ﬁve tag SNPs were chosen, which covered a
haplotype regionwith an R2 ¼ 0.85 and minor allele frequency of 
0.4 (Table 2). Genotyping for SNPs rs1247973, rs4113925, and
rs3825214 was performed using polymerase chain reaction and
restriction enzyme digestion. Genotyping for SNPs rs11067101and
Table 2
Primer sequences and RE used in TBX5 polymorphisms.
SNP No. Primer sequence PCR size and RE Allele Location HardyeWeinberg p
rs11067101 TaqMan SNP genotyping assays A/G Intron 1 1
rs2236017 TaqMan SNP genotyping assays T/G Intron 6 0.743
rs1247973 (F)50-TATACCTTCCAGCATAACTCGG-30 316 bp C/T Intron 7 0.989
(R)50-TTGACACATATTAGGGGGACAC-30 Nal III
rs4113925 (F)50-CACTCCAGCCTGGGCAACAAGA-30 271 bp A/G Intron 7 0.895
(R)50-GCAAGTCAAACCTGGCATCTGGC-30 Sal I
rs3825214 (F)50-ATTTGAATCAGGCTCCTTTACTTAATAT-30 227 bp A/G Intron 8 0.917
(R)50-TATTATTGTGAATTATGTCTGCCATAAG-3 Hind III
PCR ¼ polymerase chain reaction; RE ¼ restriction enzyme; SNP ¼ single nucleotide polymorphism.
Table 4
Associations between TBX5 genotypes and MMP9 levels.
TBX5 genotypes MMP9 levels pa
rs11067101 AA 143.79 ± 117.19 (112) 0.255
AG 137.21 ± 110.52 (283)
GG 155.93 ± 114.72 (176)
AA þ AG 139.08 ± 112.34 (395) 0.073
GG 155.93 ± 114.72 (176)
rs2236017 TT 155.69 ± 128.78 (54) 0.728
TG 140.87 ± 116.82 (257)
GG 147.69 ± 107.70 (249)
TT þ TG 143.45 ± 118.90 (311) 0.376
GG 147.69 ± 107.70 (249)
rs1247973 CC 161.14 ± 141.38 (130) 0.204
CT 138.10 ± 98.91 (286)
TT 141.49 ± 110.44 (156)
CC þ CT 145.30 ± 114.22 (416) 0.846
TT 141.49 ± 110.44 (156)
rs4113925 AA 124.02 ± 96.12 (175) 0.013
AG 153.55 ± 119.56 (276)
GG 152.36 ± 117.79 (121)
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obtained from Applied Biosystems (Foster City, CA, USA).
2.5. Statistical analysis
The Chi-square test was used for comparisons of the categorical
variables of smoking. Clinical characteristics as continuous vari-
ables were expressed as means ± standard deviation, and tested by
two-sample t test or analysis of variance. A generalized linear
model was used to analyze MMP9 levels in relation to predictors of
the investigated genotypes and confounders. Data on C-reactive
protein, serum amyloid A, soluble intercellular adhesive molecule 1,
soluble vascular cell adhesive molecule 1, SELE, soluble P-selectin,
MMP1, MMP2, MMP9, and soluble tumor necrosis factor receptor II
were logarithmically transformed prior to statistical analysis to
adhere to a normality assumption. A value of p < 0.05, using two-
sided tests, was considered statistically signiﬁcant.
Interactions between each SNP, MMP9 level, and obesity status
were tested using two-way analysis of variance. When interaction
terms were signiﬁcant, stratiﬁed analyses of the genetic variants of
the genotypes (e.g., target genotypes affected by obesity) and
MMP9 levels were performed to further investigate interactive ef-
fects while controlling for other variables including age, gender,
and smoking. The analysis of deviation from the HardyeWeinberg
equilibrium, estimation of linkage disequilibrium between poly-
morphisms, association between haplotypes and MMP9 levels, and
haplotypeeobesity interactions were performed using the Golden
Helix SVS Win32 7.3.1 software (Golden Helix, Bozeman, MT, USA).
3. Results
3.1. Clinical and biochemical characteristics
A summary of the characteristics, clinical proﬁles, and inﬂam-
matory biomarkers of the study participants (stratiﬁed by gender)
is provided in Table 1. No signiﬁcant deviation from the Har-
dyeWeinberg equilibrium was detected for the studied poly-
morphisms (p ¼ 1.00, p ¼ 0.743, p ¼ 0.989, p ¼ 0.895, and p ¼ 0.917
for SNPs rs11067101, rs2236017, rs1247973, rs4113925, and
rs3825214, respectively; Table 2). Two pairs of SNPs, rs2236017 and
rs1247973 as well as rs3825214 and rs4113925, showed strong
pairwise linkage disequilibrium (Table 3).Table 3
Linkage disequilibrium between TBX5 genetic polymorphisms.a
rs2236017 rs1247973 rs4113925 rs3825214
rs11067101 0.056170 0.19214 0.005501 0.004083
rs2236017 d 0.905577 0.421236 0.407054
rs1247973 d d 0.019257 0.050587
rs4113925 d d d 0.798946
a The values represent D0 .3.2. Associations between TBX5 gene polymorphisms and
circulating MMP9 levels
To determine whether the TBX5 genotypes affected circulating
inﬂammatory marker levels, 11 inﬂammatory markers were
analyzed, including C-reactive protein, ﬁbrinogen, serum amyloid
A, soluble intercellular adhesive molecule 1, soluble vascular cell
adhesive molecule 1, SELE, soluble P-selectin, soluble tumor ne-
crosis factor receptor II, MMP1, MMP2, and MMP9. Our results
showed that genetic variants in or around the TBX5 gene were
signiﬁcantly associated with MMP9 levels in Taiwanese individuals
(Table 4). After adjusting for clinical covariates, signiﬁcant associ-
ations with theMMP9 level were observed for two polymorphisms,
rs4113925 and rs3825214, using an additive inheritance model
(p ¼ 0.013 and p ¼ 0.019, respectively). In the dominant model,
minor alleles of rs4113925 and rs3825214 were associated with a
higher MMP9 level (p ¼ 0.002 and p ¼ 0.001, respectively).3.3. TBX5 haplotypes and MMP9 levels
As SNP regression demonstrated that multiple sites within the
TBX5 gene signiﬁcantly affected MMP9 levels, haplotypes wereAA 124.02 ± 96.12 (175) 0.002
AG þ GG 153.18 ± 118.87 (397)
rs3825214 GG 147.61 ± 101.70 (94) 0.019
GA 159.35 ± 129.01 (266)
AA 124.61 ± 92.38 (209)
GG þ GA 156.28 ± 122.44 (360) 0.001
AA 124.61 ± 92.38 (209)
Data are presented as mean ± standard deviation (N).
MMP9 ¼ matrix metalloproteinase 9; N ¼ number of subjects; SD ¼ standard
deviation.
a The p value is adjusted for age, sex, body mass index, and smoking status.
Table 6
MMP9 levels: stepwise linear regression analysis, including genotype.
Variable Beta R2a p
Gender 0.051 0.022 0.022
Age 0.003 0.001 0.001
BMI <0.001 0.003 0.939
Current smoker 0.087 0.028 0.002
Fibrinogen 0.001 <0.001 <0.001
Glucose 0.001 <0.001 0.056
SELE rs5368 TT genotype 0.155 0.044 <0.001
MMP9 rs2274756 AA genotype 0.161 0.082 0.049
TBX5 rs3825214 AA genotype 0.061 0.021 0.004
BMI ¼ body mass index; MMP9 ¼ matrix metalloproteinase 9; SELE ¼ soluble E-
selectin.
a Cumulative R2. Multiple linear regression, adjusted for age, gender, smoking
status, BMI, ﬁbrinogen, fasting plasma glucose, SELE rs5368 genotype, MMP9
rs2274756 genotype, and TBX5 rs3825214 genotype.
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investigation, two pairs of SNPs, rs2236017 and rs1247973 as well
as rs3825214 and rs4113925, showed strong pairwise linkage
disequilibrium; thus, three tag SNPs (rs11067101, rs12479730, and
rs3825214) were enrolled for haplotype analysis. Eight common
haplotypes ( 5% frequency) were derived from these three SNPs,
accounting for all inferred haplotypes. Haplotype analysis revealed
a signiﬁcant association between the TBX5 haplotype GCG and
MMP9 levels (uncorrected p¼ 0.0093 and corrected false discovery
rate p ¼ 0.0435) (Table 5).
3.4. Stepwise regression analysis of MMP9 levels using a general
linear model in the study population
In addition to the independent variables associated with MMP9
levels, as reported previously by Wu et al [29], TBX5 gene variants,
gender, and body mass index were further used for multivariate
analysis. In a stepwise regression analysis, the TBX5 SNP rs3825214
genotype with a dominant model, in addition to age, gender,
smoking status, ﬁbrinogen levels, and SELE SNP rs5368, was inde-
pendently associated with MMP9 levels (p < 0.05; Table 6).
3.5. Interactions between TBX5 genotypes/haplotypes, obesity, and
MMP9 levels
After adjusting for age, gender, and smoking status, subgroup
and interaction analyses revealed associations between rs4113925,
rs3825214, and MMP9 levels only in nonobese individuals, using a
dominant inheritance model (p ¼ 1.04  104 and p ¼ 7.11  105,
respectively; interaction p ¼ 0.0088 and interaction p ¼ 0.0183,
respectively; Fig. 1).
Subgroup analysis showed a borderline signiﬁcant association
between the haplotype GCG and MMP9 levels (uncorrected
p ¼ 0.020 and corrected false discovery rate p ¼ 0.073), but with no
evidence of interaction (interaction p ¼ 0.409) (data not shown).
4. Discussion
This investigation analyzed the association between TBX5 gene
variants and metabolic proﬁles and inﬂammatory marker levels in
Taiwanese individuals. Our data revealed signiﬁcant associations
between TBX5 genotypes/haplotypes and MMP9 levels. The asso-
ciationwithMMP9 levels is independent of our previously reported
MMP9 and SELE gene variants. Interactions between obesity, TBX5
genetic variants, and MMP9 levels were also noted. These dataTable 5
Associations between TBX5 locus haplotypes and MMP9 levels.a
Haplotype Frequency (%) MMP9 level p2
Coefﬁcient p1
H1 GCA 19.3 0.0970 0.4078 0.6493
H2 ATA 17.9 0.0291 0.0184 0.0720
H3 GTA 14.3 0.0145 0.7880 0.8589
H4 GCG 11.5 0.0669 0.0093 0.0435
H5 GTG 10.8 0.2063 0.1882 0.4298
H6 ATG 9.3 0.0495 0.7609 0.8447
H7 ACA 8.5 0.0575 0.6541 0.8244
H8 ACG 8.4 0.0886 0.1816 0.4395
MMP9 ¼matrix metalloproteinase 9; p1 ¼ uncorrected p value; p2 ¼ corrected false
discovery rate p value; SNP ¼ single nucleotide polymorphisms.
a SNP1, rs11067101; SNP2, rs1247973; SNP3, rs3825214. Coefﬁcients and p
values were estimated based on haplotype trend regression analysis implemented
in the HelixTree program. The selected haplotype was compared to all unselected
haplotypes, adjusted for age, sex, smoking, and body mass index.
Fig. 1. Interactive effect of MMP9 levels on the association betweenTBX5 genotypes and
obesity status. (A) After adjusting for clinical covariates, the major allele of rs4113925 of
the TBX5 gene was found to be associated with decreased MMP9 levels in nonobese
individuals (p ¼ 1.04  104). Interaction analysis revealed an interaction between
obesity status and the rs4113925 genotype (interaction p ¼ 0.0088 for the dominant
model, after adjustment for age, gender, and smoking status). (B) After adjusting for
clinical covariates, the major allele of rs3825214 of the TBX5gene was found to be
associated with decreased MMP9 levels in nonobese individuals (p ¼ 7.11  105).
Interaction analysis revealed an interaction between obesity status and the rs4113925
genotype (interaction p ¼ 0.0183 for the dominant model, after adjustment for age,
gender, and smoking status). MMP9 ¼ matrix metalloproteinase 9.
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that may modulate the expression of MMP9. These results also
expand our understanding of the underlying mechanism of the
association between TBX5 and cardiovascular diseases.
TBX5 is a transcriptional regulator in which mutations result in
various congenital heart diseases. Heart formation requires a highly
balanced network of transcriptional gene activation. TBX5 also
plays an important role in postnatal maturation of the AV node, AV
bundle, and left and right bundle branch patterning [30]. However,
there is no TBX5 binding site on theMMP9 promoter region; thus, it
is unlikely that TBX5 alone directly regulates the expression of
MMP9. TBX5 commonly functions with other transcription factors,
including NK2 transcription factor-related locus (NKX2-5). In a
previous investigation, Hiroi et al [31] revealed that two different
types of cardiac transcriptional factors, TBX5 and NKX2-5, directly
bound to the promoter of the gene for cardiac-speciﬁc natriuretic
peptide precursor type A (NPPA) in tandem, and both showed
synergistic activation that induced cardiac development. TBX5 also
acts cooperatively with NKX2-5 to regulate the expression of short
stature homeobox 2 and bone morphogenetic protein 4, which are
essential for the formation of the pacemaker region of the devel-
oping heart [32]. Co-occupancy of a chromatin region by multiple
transcription factors has also been shown to identify a distinct set of
developmentally relevant enhancers, including GATA4, NKX2-5,
TBX5, serum response factor, and myocyte-enhancer factor 2A
[33]. An NKX2-5-binding sitewas identiﬁed on theMMP9 promoter
region by in silico analysis (http://mbs.cbrc.jp/research/db/
TFSEARCH). Thus, it is possible that TBX5 may act with NKX2-5 to
regulate the expression of MMP9. Munshi et al [34] demonstrated
that a distal enhancer for connexin 30.2, a gap junction protein
required for normal AV delay in mice, is necessary and sufﬁcient to
direct expression to the developing AV conduction system. This
enhancer requires TBX5 and GATA4 for proper expression in the
conduction system. These results suggest the importance of TBX5
in association with other transcription factors in regulating tran-
scription and cardiac development.
Several lines of evidence suggest that MMP9 may be associated
with some TBX5-related pathologies. Both TBX5 and MMP9 have
been associated with atrial and AV conduction pathologies with
active ﬁbrotic processes. Progressive cardiac conduction disease
(PCCD), the most common cause of acquired, permanent, third-
degree AV block, is characterized by a slow, progressive loss of AV
conduction ﬁbers. Increased myocardial collagen turnover with
increased plasma MMP9 levels was observed in patients with PCCD
[35]. Cardiac remodeling induced byMMP9 appears to play a role in
the pathomechanism of AV conduction delay and ventricular dila-
tation in hyperhomocysteinemia [36]. Polymorphisms of the TBX5
gene have also been associated with genetic determinants of the PR
interval and QRS duration, markers of cardiac conduction. Atrial
ﬁbrosis in atrial ﬁbrillation is characterized by severe alterations in
collagen I and III synthesis/degradation associated with disturbed
MMP/tissue inhibitor of metalloproteinase systems [37]. Tumor
necrosis factor triggers expression and activation of MMPs,
includingMMP9, contributing to adverse myocardial remodeling in
atrial ﬁbrillation [38]. A higher risk of atrial ﬁbrillation was also
noted with TBX5 gene variants [17,18]. Thus, it is possible that TBX5
polymorphisms may act through MMP9, which results in TBX5-
related pathologies.
The possibility that MMP9 is an intermediate between TBX5 and
cardiovascular pathologies is further supported by the study of
TBX20, a closely related T-box family member of TBX5. Both TBX5
and TBX20 are crucial lineage decisive players in early myocardial
dichotomy with speciﬁcation of chamber and nonchamber
myocardium in the forming vertebral heart [39]. TBX20 mutations
also contribute to various congenital heart diseases in Chinesepatients, including atrial septal defect, total anomaly of pulmonary
venous return, and tetralogy of Fallot [40]. Similar to TBX5, cardiac
TBX20 has been shown to directly interact with NKX2-5, GATA4,
and GATA5 in the regulation of gene expression in the developing
heart [13]. More importantly, TBX20 has been shown to increase
MMP9 and MMP13 expression in primary avian endocardial cells,
which suggests an important role in extracellular matrix remod-
eling and promoting cell proliferation in mesenchymal valve pre-
cursor populations in the endocardial cushion during embryonic
development [41]. It is interesting that our data showed a signiﬁ-
cant association between TBX5 gene polymorphisms and MMP9
levels in Taiwanese individuals. Further study is necessary to
elucidate the role of the TBX20 gene in regulating MMP9 levels.
Interactions between genotypes/adiposity and lipid variables/
inﬂammatory markers have been demonstrated previously
[27,29,42,43]. The present data provide further evidence that the
interaction between obesity and TBX5 genotypes/haplotypes affects
MMP9 levels. Although there is no association between the MMP9
level and obesity, it is likely that an increased inﬂammatory status
with adiposity may affect the role of genetic effects. Our data
suggested that the genetic background associated with MMP9
levels might differ between obese and nonobese individuals.
Major limitations of the study include the use of a single pop-
ulation with a modest sample size and the cross-sectional design.
Replication in a second cohort with a larger sample size and pro-
spective design would improve the strength of the genetic associ-
ation and interaction analyses. When the false discovery rate was
applied for multiple tests in haplotype analysis, the statistical sig-
niﬁcance of a portion of our results became marginal. However, a
signiﬁcant p value was obtained in the multivariate analysis, sug-
gesting that the association between the TBX5 polymorphisms and
MMP9 levels may not be due to chance.
In conclusion, the signiﬁcant associations between TBX5 geno-
types/haplotypes and MMP9 levels observed in this investigation
suggest that MMP9 is involved in TBX5-related pathology. Our re-
sults provide an insight into the regulation and functional mecha-
nism underlying cardiac development and PCCD. The regulation of
TBX5-induced MMP9 expression might represent a new thera-
peutic target for PCCD.Acknowledgments
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